Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
Authors:
- E. SuESE. Su
- S. FischerSFS. Fischer
- R. Demmer-SteingruberRDR. Demmer-Steingruber
- S. GüsewellSGS. Güsewell
- W.C. AlbrichWAW.C. Albrich
- C. RothermundtCRC. Rothermundt
- T. SilzleTST. Silzle
- C.R. KahlertCKC.R. Kahlert
Open Access
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Prior COVID-19 protects against reinfection, even in the absence of detectable antibodiesJournal of Infection, 2021
- COVID‐19 outcomes in hospitalized patients with active cancer: Experiences from a major New York City health care systemCancer, 2021
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humansNature, 2021
- Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerCancer Discovery, 2021
- Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patientsEuropean Journal of Cancer, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 InfectionJAMA Oncology, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based studyClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Annals of Oncology, 2018